|
1
|
Falebita OA, Mancini S, Kiely E and Comber
H: Rising incidence of renal cell carcinoma in Ireland. Int Urol
Nephrol. 41:7–12. 2009. View Article : Google Scholar
|
|
2
|
Störkel S and van den Berg E:
Morphological classification of renal cancer. World J Urol.
13:153–158. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bukowski RM, Negrier S and Elson P:
Prognostic factors in patients with advanced renal cell carcinoma:
Development of an international kidney cancer working group. Clin
Cancer Res. 10:S6310–S6314. 2004. View Article : Google Scholar
|
|
4
|
Heinzelmann J, Henning B, Sanjmyatav J,
Posorski N, Steiner T, Wunderlich H, Gajda MR and Junker K:
Specific miRNA signatures are associated with metastasis and poor
prognosis in clear cell renal cell carcinoma. World J Urol.
29:367–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
An J, Liu H, Magyar CE, Guo Y, Veena MS,
Srivatsan ES, Huang J and Rettig MB: Hyperactivated JNK is a
therapeutic target in pVHL-deficient renal cell carcinoma. Cancer
Res. 73:1374–1385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeng L, Bai M, Mittal AK, El-Jouni W, Zhou
J, Cohen DM, Zhou MI and Cohen HT: Candidate tumor suppressor and
pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Cancer Res. 73:5371–5380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pal SK, He M, Tong T, Wu H, Liu X, Lau C,
Wang JH, Warden C, Wu X, Signoretti S, et al: RNA-seq reveals
aurora kinase driven-mTOR pathway activation in patients with
sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res.
13:130–137. 2015. View Article : Google Scholar
|
|
8
|
Von Schulz-Hausmann SA, Schmeel LC,
Schmeel FC and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin
pathway in renal cell carcinoma. Anticancer Res. 34:4101–4108.
2014.PubMed/NCBI
|
|
9
|
Schütte U, Bisht S, Heukamp LC, Kebschull
M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart
P and Feldmann G: Hippo signaling mediates proliferation,
invasiveness, and metastatic potential of clear cell renal cell
carcinoma. Transl Oncol. 7:309–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang D, Ding Y, Luo WM, Bender S, Qian
CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH and Teh
BT: Inhibition of MAPK kinase signaling pathways suppressed renal
cell carcinoma growth and angiogenesis in vivo. Cancer Res.
68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhan YH, Liu J, Qu XJ, Hou KZ, Wang KF,
Liu YP and Wu B: β-Elemene induces apoptosis in human renal-cell
carcinoma 786-0 cells through inhibition of MAPK/ERK and
PI3K/Akt/mTOR signalling pathways. Asian Pac J Cancer Prev.
13:2739–2744. 2012. View Article : Google Scholar
|
|
12
|
Du HF, Ou LP, Song XD, Fan YR, Yang X, Tan
B, Quan Z, Luo CL and Wu XH: Nuclear factor-kB signaling pathway is
involved in phospholipase Cε-regulated proliferation in human renal
cell carcinoma cells. Mol Cell Biochem. 389:265–275. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Munshi A and Ramesh R: Mitogen-activated
protein kinases and their role in radiation response. Genes Cancer.
4:401–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J and Lin A: Role of JNK activation in
apoptosis: A double-edged sword. Cell Res. 15:36–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cimino D, De Pittà C, Orso F, Zampini M,
Casara S, Penna E, Quaglino E, Forni M, Damasco C, Pinatel E, et
al: miR148b is a major coordinator of breast cancer progression in
a relapse-associated microRNA signature by targeting ITGA5, ROCK1,
PIK3CA, NRAS and CSF1. FASEB J. 27:1223–1235. 2013. View Article : Google Scholar
|
|
16
|
Liu GL, Liu X, Lv XB, Wang XP, Fang XS and
Sang Y: miR-148b functions as a tumor suppressor in non-small cell
lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin
Exp Med. 7:1990–1999. 2014.PubMed/NCBI
|
|
17
|
Zhang Z, Zheng W and Hai J: MicroRNA-148b
expression is decreased in hepatocellular carcinoma and associated
with prognosis. Med Oncol. 31:9842014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao G, Zhang JG, Liu Y, Qin Q, Wang B,
Tian K, Liu L, Li X, Niu Y, Deng SC and Wang CY: miR-148b functions
as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol
Cancer Ther. 12:83–93. 2013. View Article : Google Scholar
|
|
19
|
Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu
HM, Zhang X, Jiang L, Xing CZ and Zhang Y: MicroRNA-148b is
frequently down-regulated in gastric cancer and acts as a tumor
suppressor by inhibiting cell proliferation. Mol Cancer. 10:12011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song Y, Xu Y, Wang Z, Chen Y, Yue Z, Gao
P, Xing C and Xu H: MicroRNA-148b suppresses cell growth by
targeting cholecystokinin-2 receptor in colorectal cancer. Int J
Cancer. 131:1042–1051. 2012. View Article : Google Scholar
|
|
21
|
Fawdar S, Trotter EW, Li Y, Stephenson NL,
Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller
CJ and Brognard J: Targeted genetic dependency screen facilitates
identification of actionable mutations in FGFR4, MAP3K9, and PAK5
in lung cancer. Proc Natl Acad Sci USA. 110:12426–12431. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ribeiro J, Marinho-Dias J, Monteiro P,
Loureiro J, Baldaque I, Medeiros R and Sousa H: miR-34a and
miR-125b expression in HPV infection and cervical cancer
development. Biomed Res Int. 2015:3045842015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lyu Z, Mao Z, Wang H, Fang Y, Chen T, Wan
Q, Wang M, Wang N, Xiao J, Wei H, et al: MiR-181b targets Six2 and
inhibits the proliferation of metanephric mesenchymal cells in
vitro. Biochem Biophys Res Commun. 440:495–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grange C, Collino F, Tapparo M and Camussi
G: Oncogenic micro-RNAs and renal cell carcinoma. Front Oncol.
4:492014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Durkin JT, Holskin BP, Kopec KK, Reed MS,
Spais CM, Steffy BM, Gessner G, Angeles TS, Pohl J, Ator MA and
Meyer SL: Phosphoregulation of mixed-lineage kinase 1 activity by
multiple phosphorylation in the activation loop. Biochemistry.
43:16348–16355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stronach B, Lennox AL and Garlena RA:
Domain specificity of MAP3K family members, MLK and Tak1, for JNK
signaling in drosophila. Genetics. 197:497–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bisson N, Tremblay M, Robinson F, Kaplan
DR, Trusko SP and Moss T: Mice lacking both mixed-lineage kinase
genes Mlk1 and Mlk2 retain a wild type phenotype. Cell Cycle.
7:909–916. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
|
